Matinas BioPharma
MTNB
23 hedge funds and large institutions have $199K invested in Matinas BioPharma in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.46% less ownership
Funds ownership: 5.53% → 5.07% (-0.46%)
4% less funds holding
Funds holding: 24 → 23 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
35% less capital inflows, than outflows
Capital inflows: $28.9K | Capital outflows: $44.8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$27.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.14K |
| 3 |
BlackRock
New York
|
+$396 |
| 4 |
IFG Advisory
Atlanta,
Georgia
|
+$10 |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$10 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$23.3K |
| 2 |
XTX Topco
George Town,
Cayman Islands
|
-$10.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$10.3K |
| 4 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
-$618 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$92 |
MTNB Hedge Fund Activity: Q2 2026 in Review
23 of the 8,353 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2026, worth a combined $199K — up 12% from $177K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of MTNB and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $27.4K. The largest seller was Citadel Advisors, cutting an estimated $23.3K.
- 23 institutional investors held Matinas BioPharma (MTNB) as of Q2 2026, down from 24 in Q1 2026.
- Funds reported $199K of Matinas BioPharma stock for Q2 2026, up 12% quarter-over-quarter.
- 2 funds opened new Matinas BioPharma positions in Q2 2026 and 3 closed out, a net change of -1 holder.
- The largest Matinas BioPharma buyer in Q2 2026 was Renaissance Technologies, an estimated $27.4K added.
- The largest Matinas BioPharma seller in Q2 2026 was Citadel Advisors, an estimated $23.3K sold.
Based on aggregated 13F filings for Q2 2026.